{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:29Z","timestamp":1790806829428,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.oret.2025.01.012","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:19:13Z","timestamp":1737400753000},"page":"677-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Meta-Analysis of Intravitreal Ranibizumab versus Laser Photocoagulation for the Treatment of Retinopathy of Prematurity"],"prefix":"10.1016","volume":"9","author":[{"given":"Abed A.","family":"Baiad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace S.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamiar","family":"Mireskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.01.012_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/archdischild-2016-310532","article-title":"Epidemiology of blindness in children","volume":"102","author":"Solebo","year":"2017","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.oret.2025.01.012_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.01.012_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.012_bib4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: a review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib5","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.012_bib6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0161-6420(93)31664-7","article-title":"Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study","volume":"100","author":"Hunter","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.012_bib8","first-page":"233","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.oret.2025.01.012_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40942-023-00456-x","article-title":"Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment","volume":"9","author":"Asano","year":"2023","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2025.01.012_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaapos.2006.05.005","article-title":"Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity","volume":"10","author":"McLoone","year":"2006","journal-title":"J AAPOS"},{"key":"10.1016\/j.oret.2025.01.012_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.01.012_bib12","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2025.01.012_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.oret.2025.01.012_bib14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3,701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib16","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.oret.2025.01.012_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.oret.2025.01.012_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.01.012_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.01.012_bib22","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.01.012_bib23","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.oret.2025.01.012_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.01.012_bib25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/aje\/kwm189","article-title":"Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles","volume":"166","author":"Shrier","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.oret.2025.01.012_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.oret.2025.01.012_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12886-023-02886-5","article-title":"Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib28","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s00417-022-05663-0","article-title":"Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection","volume":"260","author":"Lu","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the rainbow trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.012_bib30","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1038\/s41598-021-83985-5","article-title":"Management of retinopathy of prematurity (ROP) in a Polish cohort of infants","volume":"11","author":"Chmielarz-Czarnoci\u0144ska","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.01.012_bib31","first-page":"1556","article-title":"Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity","volume":"104","author":"Zhao","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti\u2013vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.012_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-019-1067-4","article-title":"Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study","volume":"19","author":"Lyu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.oret.2025.01.012_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.012_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.oret.2025.01.012_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.51847\/6vtXeVdItu","article-title":"Comparative analysis of intravitreal ranibizumab versus laser therapy for retinopathy of prematurity","volume":"13","author":"Elabbasy","year":"2022","journal-title":"Arch Pharm Pract"},{"key":"10.1016\/j.oret.2025.01.012_bib38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2018-312272","article-title":"Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety","volume":"103","author":"Kang","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.01.012_bib41","first-page":"14","article-title":"Physiological and anaesthetic considerations for the preterm neonate undergoing surgery","volume":"1","author":"Taneja","year":"2012","journal-title":"J Neonatal Surg"},{"key":"10.1016\/j.oret.2025.01.012_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1159\/000531541","article-title":"A meta-analysis of neurodevelopmental outcomes following intravitreal bevacizumab for the treatment of retinopathy of prematurity","volume":"120","author":"Baiad","year":"2023","journal-title":"Neonatology"},{"key":"10.1016\/j.oret.2025.01.012_bib43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/aos.14406","article-title":"Inadequate laser coagulation is an important cause of treatment failure in type 1 retinopathy of prematurity","volume":"98","author":"Spandau","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ophtha.2018.12.012","article-title":"Laser treatment for retinopathy of prematurity: a decade since ETROP","volume":"126","author":"Emami","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.012_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1202927","article-title":"Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis","volume":"11","author":"Alva","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.oret.2025.01.012_bib46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41433-019-0605-x","article-title":"Is the severity of refractive error dependent on the quantity and extent of retinal laser ablation for retinopathy of prematurity?","volume":"34","author":"Young-Zvandasara","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.01.012_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279898","article-title":"Association between myopia progression and quantity of laser treatment for retinopathy of prematurity","volume":"17","author":"Hwang","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.01.012_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.siny.2021.101274","article-title":"Neurological and developmental outcomes following neonatal encephalopathy treated with therapeutic hypothermia","volume":"26","author":"Marlow","year":"2021","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.oret.2025.01.012_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaapos.2012.10.025","article-title":"Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity Study: findings at 4 to 6 years of age","volume":"17","author":"Quinn","year":"2013","journal-title":"J AAPOS"},{"key":"10.1016\/j.oret.2025.01.012_bib50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.012_bib51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"10.1016\/j.oret.2025.01.012_bib52","doi-asserted-by":"crossref","first-page":"lsac001","DOI":"10.1093\/jlb\/lsac001","article-title":"Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases","volume":"9","author":"Van de Wiele","year":"2022","journal-title":"J Law Biosci"},{"key":"10.1016\/j.oret.2025.01.012_bib53","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.ophtha.2020.06.012","article-title":"Intravitreal anti\u2013vascular endothelial growth factor cost savings achievable with increased bevacizumab reimbursement and use","volume":"127","author":"Glasser","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.012_bib54","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamapediatrics.2015.1305","article-title":"Epidemiologic trends in neonatal intensive care, 2007-2012","volume":"169","author":"Harrison","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.oret.2025.01.012_bib55","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4103\/jfmpc.jfmpc_110_20","article-title":"Retinopathy of prematurity: addressing the emerging burden in developing countries","volume":"9","author":"Senjam","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.oret.2025.01.012_bib56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/08820538.2022.2152708","article-title":"Global disparities in retinopathy of prematurity: a literature review","volume":"38","author":"Ahmed","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bjophthalmol-2017-310709","article-title":"A worldwide survey of retinopathy of prematurity screening","volume":"102","author":"Mora","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.012_bib58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41433-019-0643-4","article-title":"Retinopathy of prematurity treatment: Asian perspectives","volume":"34","author":"Sen","year":"2020","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:11:19Z","timestamp":1777633879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2468653025000144"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.012","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Meta-Analysis of Intravitreal Ranibizumab versus Laser Photocoagulation for the Treatment of Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00c2\u00a9 2025 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}